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Abstract
Standard approach to the treatment of head and neck cancer include surgery, chemotherapy, and
radiation. More recently, dramatic increases in our knowledge of the molecular and genetic basis
of cancer combined with advances in technology have resulted in novel molecular therapies for this
disease. In particular, gene therapy, which involves the transfer of genetic material to cells to
produce a therapeutic effect, has become a promising approach. Clinical trials concerning gene
therapy strategies in head and neck cancer as well as combination of these strategies with
chemotherapy and radiation therapy will be discussed.
Introduction
The prognosis of patients with Squamous Cell Carcinoma
of the Head and Neck (SCCHN) is poor. The National
Cancer Institute (NCI) reported in its SEER Cancer Statis-
tic Review that there are approximately 40,000 new cases
of primary head and neck cancer in the United States each
year. The incidence of this cancer has been gradually
increasing over the past 20 years and it is now the fifth
leading cause of cancer incidence and the sixth leading
cause of cancer-related death in the world [1]. Patients
with early stage disease are treated with surgery or radia-
tion therapy. However, despite advances in surgical resec-
tion, radiation techniques and adjuvant treatment,
survival in these patients has not improved significantly
over the past 30 years and one third of these patients
develop local and/or regional tumor recurrence following
surgery. In patients with locoregional disease, significant
strides have been made in achieving excellent local con-
trol. However, nearly half of patients who undergo treat-
ment for locally advanced disease will experience local or
distant relapse. When patients experience treatment fail-
ure with first-line therapy, median survival time
approaches 3 to 4 months, even with treatment. Therefore
new treatment options are desperately needed and gene
therapy offers hope in this regard. The goal of gene ther-
apy is to introduce new genetic material into cancer cells
that will selectively kill cancer cells with no toxicity to the
surrounding non-malignant cells. In HNSCC this is an
attractive treatment for two reasons. First, tumors are
often accessible for direct injection of genetic therapeutic
agents. Second, locoregional failure remains the predom-
inant pattern of failure and cause of death among patients
with recurrent disease. Recently, clinical trials of gene
therapy in SCCHN have been completed and many data
suggest the possibility and feasibility of this approach
together with more conventional modality treatment such
as radiation therapy and chemotherapy.
Gene therapy involves the introduction of foreign DNA
into somatic cells to produce a therapeutic effect [2]. A
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variety of vectors have been used to transfer genes into
cells. Viral vectors remain the gene transfer vehicles of
choice, with retroviral and adenoviral vectors constituting
25% of all viral vectors currently in use in clinical trials.
Several strategies have been developed for cancer gene
therapy including 1) Replacement of tumor suppressor
gene function; 2) Blockage of dominant oncogene func-
tion; 3) Oncolytic virus therapy, which selectively kill
tumor cells but not normal cells; 4) Genetic prodrug acti-
vation therapy; 5) Genetic immunomodulation. These
approaches may converge and can often be used in com-
bination to amplify potential therapeutic effects. This
review presents an update on the clinical results obtained
in the field of HNSCC cancer gene therapy.
Advexin (INGN 201, Ad5CMV-p53)
Advexin (INGN 201, Ad5CMV-p53; Introgen Therapeu-
tics, Inc.) is an adenovirus (type 5) in which the E1 region
is replaced with the cDNA of the p53 gene and is driven
by a cytomegalovirus (CMV) promoter [3]. Deletion of
the E1 region of the parental Ad5 DNA renders Advexin a
replication-defective virus and prevents the expression of
adenoviral genes. Studies with repeated sequencing
showed that Advexin does not undergo mutational
changes, and it maintains wild-type p53 DNA throughout
the manufacturing process. The p53 gene is located on
chromosome 17p in humans and it encodes a 393 amino
acid protein that is critical to tumor biology [4]. Inactiva-
tion of p53 signaling pathways can allow proliferation of
damaged cells and result in tumor formation. Delivery of
the wild type p53 gene to a cancer cell via a modified ade-
noviral vector induces expression of wild-type p53 protein
and triggers growth arrest or apoptosis, causing tumor
growth inhibition.
A phase I trial carried out at the MD Anderson Cancer
Center, Texas, USA, in patients with advanced local or
regional head and neck cancer that was unresectable was
reported by Clayman [5,6]. Thirty-three patients were
treated by multiple intratumoral injections of Advexin at
a dose of 10/11 pfu three times a week (this made up one
course). Patients with resectable tumors received one full
course of treatment and two additional administrations
followed, one during surgery and one 72 hours after sur-
gery. Patients with unresectable tumors received a treat-
ment every 4 weeks. The treatment regimen was well
tolerated and no serious side effects were reported.
Patients with resectable versus non-resectable disease
were analyzed separately. Of the non-resectable arm, 2
out of 17 patients had major responses (11.8%), six
showed stable disease up to 3.5 months and nine showed
progressive disease. Of the resectable arm, 4 of 15 patients
remained free of disease with a median follow up of 18
months, which was greater than that expected for recur-
rent resectable SCCHN disease. In particular, one patient
had a pathologic complete response at the time of surgery
and remained free of disease 26 months after the initial
treatment. Another patient also had no evidence of dis-
ease at 24 months. Moreover, analysis of tumor biopsies
showed expression of the p53 transgene and evidence of
apoptosis was also detectable. In this well conducted
study not only issues pertaining to safety but also the
kinetic of the vector employed were addressed. Ad-p53
was detected in blood by PCR by 30 minutes after injec-
tion and gradually eliminated over the next 48 hours.
Cytopathic effect assays performed in patients treated at
the highest 2-dose levels showed that viable Adp53 was
present in blood at the highest levels 30 minutes after
intratumoral injections, decreased at a rate of 2–4 orders
of magnitude by 90 minutes and further decreased to very
low or undetectable titers by 24 hours to be completely
eliminated by 48 hours after injections. Ad-p53 was
detected also in the urine from some patients who
received doses of 3 × 10^9 pfu or greater and was present
in urine from all patients who received doses of 3 × 10^10
pfu or greater. Ad-p53 detection in urine started within
one day of the beginning of p53 injections. Urine was free
of Adp53 within 3–17 days of the last Ad-p53 injections.
Ad-p53 was also detected in the sputum and/or saliva
samples of 6 high-dose patients tested. As with urine sam-
ples, Ad-p53 was detected within one day of injection, was
present for several days after the last injection of the virus
and was cleared to background levels within 7-days.
Although Ad-p53 was detected in blood, urine and spu-
tum, no patients reported viremic symptoms and 2 health
providers with the greater risk of exposure were tested. No
elevation of neutralizing antibodies was observed in their
serum, and neither serum nor urine contained infectious
p53 particles or Ad-p53 DNA.
Two phase II trials (T-201 and T-202) using this vector
(ING-201) have been concluded at many centers and
early results in 170 patients receiving intratumoral injec-
tion of Ad-p53 over a variety of doses and schedules
showed that treatment with ING-201 is safe and effective
[7]. The patient characteristics were similar in both trials,
but the dosage was 50-fold greater in the study T201 than
in T202. Although response rates were similar, the median
survival duration was higher (6.2 vs. 3.8 months) and the
mortality rate over the first 150 days (40 vs. 60) was lower
in the high-dose compared with the low-dose study.
Patients were not re-injected with Advexin during follow-
up and this may have contributed to the loss of effect after
the first 150 days. On the basis of these results, the use of
higher doses and multiple administrations of Advexin
were recommended for future studies. Another interesting
data emerged from such studies while responses occurred
regardless of the endogenous p53 status of the tumor. In
fact, objective responses were documented in tumors in
which no p53 mutations were found.Head & Neck Oncology 2009, 1:3 http://www.headandneckoncology.org/content/1/1/3
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There are two ongoing phase III trials to compare the
safety, efficacy and overall survival of treatment with
Advexin as monotherapy or in combination with chemo-
therapy in patients with head and neck cancer. In one of
these trials (T301), patients with local or regional recur-
rent refractory SCCHN who have failed radiation therapy
and chemotherapy with platinum-containing drugs or
taxanes were randomized to either Advexin intratumoral
or methotrexate intravenously. Patients were treated for a
maximum of nine cycles (27-weeks). Survival was the pri-
mary end point of the study and predicted accrual to
accomplish this endpoint was 240 patients. In the second
study (T302), patients with local or regional recurrent
SCCHN who have not been previously exposed to chem-
otherapy were randomized to receive a combination of
intratumoral Advexin, cisplatin and 5-fluorouracil (5-FU)
or standard care with cisplatin/5-FU. The primary end
point was time to progression and predicted accrual to
accomplish this endpoint was 288 patients.
Gencidine
Gendicine is another different molecular entity that com-
bines an Adenovirus type 5 vector with a p53 expression
cassette, using the RSV promoter and BGH (A) tail [8].
In a Phase I trial using the adenoviral vector SCH-58500,
16 patients with HNSCC received escalated doses ranging
from 7.5 × 10^9 PFU to 7.5 × 10^12 PFU. Toxicity was
limited to grade 1–2 fever and injection pain. One patient
achieved a partial remission (PR), which correlated with
the induction of apoptosis and transgene expression [9].
Recently, the first randomized clinical trial of p53 gene
therapy was reported. Ninety patients with SCCHN were
randomly allocated to receive either intratumoral injec-
tions of Ad-p53 in combination with radiation therapy
(70 Gy/8 weeks) or radiation therapy alone. Complete
remission was seen in 64.7% of patients receiving Ad-p53
combined with radiation therapy compared with 20% of
patients receiving radiation therapy alone, which was sta-
tistically highly significant [10]. This clinical trial formed
the basis for approval in head and neck cancer of Ad-p53
by the China State Food and Drug Administration, thus
making Ad-p53 the first gene therapy approved for
humane use [11,12].
Onyx (DL1520)
ONYX is a replication-conditional adenovirus that is
defective in the early regulator protein E1B, which binds
to and inactivates p53 to promote its own activation [13].
Cells containing an intact p53 pathway are thus predicted
to inhibit replication of an E1B 55 kD-deficient virus. In
contrast, p53-deficient cells, such as those of a tumor,
would be expected to allow efficient viral replication and
subsequent cell killing. However several groups demon-
strated that ONYX-015 efficiently replicates in many
tumor cells types with wild-type p53 [14,15]. This appar-
ent contradiction was resolved through examinations of
p14ARF, a tumor suppressor gene whose product func-
tionally stabilizes p53 [16]. Loss of p14ARF was identified
as a mechanism that allows ONYX-015 replication in
tumor cells retaining wild-type p53 [17].
A dose-escalation phase I trial was carried out by Ganly
[18]. A total of 22 patients with recurrent head and neck
cancer participated in this clinical trial. ONYX injection
was performed intratumorally. This study showed no seri-
ous toxicity by intratumoral injection up to a viral dose of
1 × 10^11 plaque forming units (pfu) and dose-limiting
toxicity was not reached at the highest dose of 10(11)
plaque-forming units. However, using conventional
response criteria, no objective responses were observed.
A subsequent phase II trial showed enhanced efficacy
when the virus was given by multiple daily injections in
the same group of patients [19,20]. In this study, patients
either received single daily dose (n = 30) or fractionated
twice daily dosing of dl1520 (n = 10). 14% of the patients
receiving a single daily dose of dl1520 achieved a partial
or complete response versus 10% of the patients receiving
fractionated daily doses, which was not significant in this
small study. Interestingly, response and viral replication
was correlated with p53 status by gene sequencing and
immunohistochemistry, with 58% (7 of 12) of p53
mutant tumors showing regression compared with no
response among the p53 wild-type tumors. Furthermore,
necrosis was confined to treated tumor tissue with no
damage to adjacent normal tissue. Viral spread was docu-
mented in tumor tissue 5–14 days after treatment, even in
the presence of high neutralizing antibody titers.
The viral construct DL1520 has also been employed in
chemoprevention as a mouthwash preparation for
patients with oral leucoplachia and displasia [21]. 19
assessable patients with histological confirmed oral dys-
plasia had ONYX-015 administered as a mouthwash.
Three different regimens were studied. In regimen 1, the
virus was given as a mouthwash at a dose of 1 × 10^10 pfu
daily for 5 days, with cycles repeated four times weekly for
a maximum of 12 cycles. Two of 4 patients treated had
histological resolution of the dysplasia after six cycles.
This was, however, short-lived, and the disease recurred in
both patients. Therefore, regimen 2 employed a more fre-
quent administration of virus at 1 × 10^10 pfu weekly for
24 weeks. In this regimen, four of twelve patients had
complete resolution. This was, again, short-lived in two
patients (recurrence at 24 weeks and 48 weeks, respec-
tively), but a durable response was observed in one
patient with no recurrence at a 30 months follow-up. In
regimen 3, the virus was administered to three patients atHead & Neck Oncology 2009, 1:3 http://www.headandneckoncology.org/content/1/1/3
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a higher dose of 1 × 10^11 pfu daily for 5 days, followed
by weekly administration for 5 weeks. In one patient, a
complete response occurred that was also durable with no
recurrence by 30 months post treatment. The treatment
was well tolerated and histological resolution of displasia
was seen in 37% of patients, although the effects were
generally not sustained after discontinuation. This activity
of ONYX-015 correlated with a decrease in p53 positivity.
Nonetheless, this clinical trial establishes the need for a
larger phase II/III trial to determine the activity of ONYX-
015 mouthwash in the treatment of premalignant oral
dysplasia. More detailed analysis of p53 status is also
required, such as p53 gene sequencing, mdm2 expression,
and p14ARF expression. In addition, combination treat-
ment with novel agents that act in a p53-independent
manner should also be considered. For example, isotretin-
oin works most effectively in dysplastic lesions without
dysfunctional p53. Combination with ONYX-015 may
therefore be additive due to the different mechanisms of
action on tumor cells heterogeneous in p53 status. More-
over, potential synergy may exist between the two agents
since isotretinoin has been shown to reverse differentia-
tion in hyperplasic oral lesions. This would allow ONYX-
015 to penetrate the basal layer of the epithelium of dys-
plastic lesions more effectively. Therefore, a phase II trial
in combination with isotretinoin should also be consid-
ered.
Two interesting Phase II clinical trials have showed the
feasibility and the preliminary efficacy of ONYX in associ-
ation with chemotherapy [22,23]. Both these trials evalu-
ated the use of intratumoral dl1520 injection in
combination with cisplatin and 5-fluorouracil therapy in
patients with recurrent squamous cell carcinoma of the
head and neck. In the largest trial, reported by Khuri [22],
37 patients were enrolled and assessed for toxicity and 30
patients were assessable for response. Sixty-three percent
of patients (19 of 30) had a measurable decrease in tumor
size (> 50%). Eight of 30 (27%) had complete responses
(no measurable disease), whereas 11 of 30 (36%) had
partial regression (decrease of 50–100% in tumor area).
Persistent response was confirmed 4 or more weeks after
the initial response in 15 of the 19 patients (73%). After 6
months, none of the 19 tumors with an objective response
had progressed, whereas all uninjected tumors treated
with chemotherapy alone had progressed. In the smaller
trial, reported by Lamont [23], 14 patients were enrolled
and an overall response rate of 78% has been reported.
These results are exciting if compared with historical data
of a 14% measurable response (> 50%) in patients treated
with dl1520 alone and 30–40% response for chemother-
apy alone. The combination therapy was well tolerated
and did not lead to an apparent increase in toxicity. The
most frequent adverse event was injection-site pain (53%)
that was mild (grade 1 or 2) and lasted less than 24-hours
in the vast majority of affected patients. Only one patient
discontinued therapy because of injection-site pain. Other
grade 3 or 4 toxicity that occurred in patients receiving the
combination included syncope, renal failure, facial
edema, and anorexia. Most importantly, it was also shown
that viral replication was not inhibited by this chemother-
apy regimen. In addition, the response did not correlate
with initial tumor size, presence of pretreatment neutral-
izing antibodies, TP53 gene status, or prior treatments.
Median survival time was 10.5 months and the 1-year sur-
vival rate was estimated at 32%. Although the mechanism
of the enhanced effects of combining oncolytic virother-
apy and chemotherapy is unknown, several hypotheses
exist. Intratumoral adenoviral replication results in the
expression of proapoptotic molecules, including tumor
necrosis factor, which presence could improve the efficacy
of selected chemotherapeutic drugs in inducing apoptosis
[24]. Another hypothesis rests on the fact that the induc-
tion of S phase by E1A adenoviral proteins could produce
cell cycle-mediated chemo-sensitivity. Adenoviruses are
known to induce the entry of cells into the S-phase, which
could augment the effect of concurrently used chemother-
apeutic agents. This hypothesis is further confirmed by the
ability of adenoviruses to induce the expression of topoi-
somerase I [25]. Finally, E1A gene expression, occurring
after ONYX-015 infection, can augment both p53-
dependent and p53-independent tumor cell killing
[26,27]. On the basis of these promising results an ongo-
ing Phase III study, randomizing patients who have failed
radiation therapy for recurrent head and neck cancer
between treatment with ONYX-015 in combination with
5-FU/cisplatin versus 5FU/cisplatin alone is being con-
ducted.
H-101
H-101 is an E1B-55k and partly E3 deleted adenoviral vec-
tor comparable to ONYX-015. In a randomized phase III
clinical trial of H-101 in combination with cisplatin and
5-FU, virus particles were administered by intratumoral
injection daily for five consecutive days every three weeks
[28]. A response rate of 39% was observed for chemother-
apy alone, while chemotherapy and H-101 produced a
78% response rate. Common side effects were well toler-
ated by all the patients treated with H-101 an were fever,
injection site reaction and influenza like symptoms. Sur-
vival data have not reported yet. On the basis of these
results, in 2005 a Chinese company, Shanghai Sunway
Biotech Co Ltd, was permitted to sell H-101 for the treat-
ment of head and neck cancer in China.
Liposome E1A (tgDCC-E1A)
The E1A gene functions as a tumor inhibitor by repressing
oncoproteins and sensitizing cancer cells to chemothera-
peutic and radiation treatments. The interaction of E1A, a
nuclear phosphoprotein with a wide range of cellular pro-Head & Neck Oncology 2009, 1:3 http://www.headandneckoncology.org/content/1/1/3
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teins in multiple signal transduction pathways (cell cycle,
DNA damage, histone deacetylation), results in multiple
biological activities. E1A was initially appreciated for its
ability to repress transcription, leading to down regula-
tion of HER-2/neu protein and resulting in loss of malig-
nant phenotypes. The anti-oncogenic activity of the E1A
gene, however, is not limited to tumors that overexpress
HER-2/neu. E1A also modulates expression of other
genes, resulting in differentiation of certain cancer cells. It
has also been shown to enhance antitumor activity in
response to VP16, cisplatin, paclitaxel, and adriamycin.
Several studies have also demonstrated a significant
tumor radiosensitisation response to E1A therapy. Clini-
cal investigations using cationic liposomes mixed with
plasmid DNA encoding for E1A have shown safety and
efficacy in animal models, as well as preliminary safety
and activity in clinical trials. In one small pilot study, nine
patients with recurrent, unresectable breast cancer and
nine patients with recurrent, unresectable HNSCC, the
E1A gene was administered using a lipid complex. No
toxic effects were observed and the highest dose of drug
treatment that does not cause unacceptable side effects
(MTD) was not reached [29]. In a subsequent study, 24
patients with recurrent HNSCC have been treated with
good tolerance [30]. However, clinical activity was modest
with a median overall survival of only 4.6 months.
HLA-B7 plasmid (Allovectin-7)
In 1 trial, 9 patients with advanced SCCHN who did not
express the HLA-B7 antigen received intratumoral injec-
tion of an HLA-B7 plasmid (Allovectin-7). No toxic effects
were observed. Four of 9 patients achieved a partial
response and induction of HLA-B7 expression was con-
firmed in 2 of 4 patients who responded [31]. On the
basis of these data an ongoing phase II trial involving
multiple injections of Allovectin-7 have been started.
Conclusions and future directions
The literature is full of preclinical studies describing gene
therapy products employed as anticancer agents. However
only a few of these approaches have been tested in clinical
trials. This review focuses only on gene therapy strategies
applied in clinical setting in head and neck cancer patients
where the results of clinical trials have been reported.
Several important observations can be made from the
clinical trials performed to date. Non-replicating and con-
ditional replicating adenoviral vector are the most inter-
esting gene therapy strategies explored in HNSCC.
Intratumoral administration of these products is easy and
possible, since these tumors are often accessible for direct
injection.
As anticancer agents, viral products have an excellent pro-
file and do not appear to enhance the toxicity of either
chemotherapy or radiation making them good candidates
for combined modality treatment strategies.
The most frequently reported adverse events with adeno-
viral products are fever and chill, asthenia, injection site
pain, nausea and vomiting. However, the vast majority of
these adverse events are mild to moderate.
Efficacy is limited to loco-regional control. In head and
neck cancer, local and/or regional tumor recurrence devel-
ops in approximately one-third of patients, despite defin-
itive treatment. Two-thirds of patients dying of this
disease have no evidence of symptomatic distant metas-
tases. Therefore, local and regional disease control is par-
amount in this disease, underscoring an urgent need for
more effective local therapies. The promise of adenovirus-
mediated gene therapy has not yet translated in patient
survival primarily because of the inability to deliver the
therapeutic gene to a large number of cells. Further opti-
mization of vectors will be essential for the improvement
of clinical effectiveness of cancer gene therapy.
Although preliminary clinical data are encouraging, well-
designed studies are needed for evaluation of these new
anticancer agents before their approval in clinical practice.
Approval of adenoviral products in China for treatment of
SCCHN has been subject of many controversies in the
USA. Approval should be based on multi-center, multina-
tional randomized studies planned to follow up patients
in order to evaluate survival endpoint. Moreover, correla-
tive endpoints, including assessment of expression of the
transferred genes, immunologic response to transgenes
and vectors, vector kinetics and verification of viral repli-
cation, if replicating vectors are employed, are crucial in
order to validate the clinical utility of a given approach in
combination with more traditional endpoint such as
safety and efficacy.
Lastly, because gene therapy involves introducing changes
to the body's set of genetic instructions, there are some
important ethical issues that need to be considered on the
use of gene therapy. Besides the classical concerns about
the cost of gene therapy and availability to the general
population, there are some safety issues that need to be
considered. Recently, it has been described that somatic
gene therapy resulted in an inheritable change to the
genome of rats [32]. This phenomenon has been
described as the breach of the Weismann barrier. The
Weismann barrier is described as the principle that hered-
itary information flow from germline cells to the somatic
cells only and not vice versa. The permeability of the Weis-
mann barrier introduces new ethical problems (such
those related to germline gene therapy) that were not con-
sidered previously when conducting somatic gene therapy
and that will now need to be considered in the future.Head & Neck Oncology 2009, 1:3 http://www.headandneckoncology.org/content/1/1/3
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